Welcome to our dedicated page for Qualigen Therapeutics SEC filings (Ticker: QLGN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
AIxCrypto Holdings filings document the completed rebrand from Qualigen Therapeutics and the company’s transition into AI and blockchain-enabled digital infrastructure. Recent Form 8-K disclosures cover operating and financial results, Regulation FD updates, material agreements, and corporate developments related to Real World Asset tokenization, AI agents, Embodied AI infrastructure, and digital-asset strategy.
The filing record also details private-placement financing, common and preferred stock matters, shareholder voting, board and committee governance, and amendments to entrusted investment and securities purchase agreements involving Faraday Future securities. These disclosures show how the company reports capital structure, control relationships, and strategic execution after its business transformation.
AIxCrypto Holdings, Inc. (QLGN) reported that Nasdaq notified the company it had failed to comply with Listing Rule 5635(b), which requires shareholder approval before an issuance of securities that results in a change of control. The issue related to a $41,000,000 PIPE financing that closed on September 29, 2025, involving 337,432 shares of common stock and 17,783 shares of Series B Convertible Preferred Stock sold to investors including Faraday Future Intelligent Electric Inc.
Nasdaq determined that this financing, together with significant board and management changes involving Faraday-affiliated individuals, constituted a change of control without prior shareholder approval. The company later obtained majority shareholder approval, and Nasdaq informed it that the deficiency was remediated and the matter closed, with no impact on the current listing of its common stock. Separately, on November 19, 2025, Nasdaq confirmed the company is in compliance with Listing Rule 5550(b)(1) on stockholders’ equity, but the company will remain under a one-year Panel Monitor period.
AIxCrypto Holdings, Inc., formerly operating under the Nasdaq ticker QLGN, reported that it has launched a new corporate name and trading symbol “AIXC”. The company marked this rebranding with a presentation at Nasdaq headquarters, where it highlighted the new name and elements of an updated business plan focused on its AI and crypto-related strategy.
The company also issued a press release on November 20, 2025, announcing the rebranding and updated business plan, which is included as an exhibit to this report. A video link to the Nasdaq presentation was provided for investors and the public to review the company’s new positioning and strategic direction.
Qualigen Therapeutics, Inc. announced several board changes effective November 17, 2025. The Nominating and Governance Committee appointed Koti Meka, the Company’s Chief Financial Officer who also serves as CFO of Faraday Future Intelligent Electric Inc., as an Executive Director. The Committee also named Jie Sheng, Head of Operations & Finance Director of FF Global Partners LLC, as Chairman of the Board of Directors.
On the same date, Chad Chen, already a board member, was appointed to the Board’s Audit Committee. The Company states there are no compensation arrangements, plans, or agreements entered into with the newly appointed board members. Directors Graydon Bensler and Braeden Lichti resigned from the Board, and their resignations were noted as not resulting from any disagreements regarding the Company’s operations, policies, or practices.
Qualigen Therapeutics, Inc. reported that it has amended its charter in Delaware to change its corporate name to AIxCrypto Holdings, Inc. The company expects its common stock to stop trading under the ticker “QLGN” and begin trading on the Nasdaq Capital Market under the new symbol “AIXC” as promptly as possible. The name change does not alter the rights of existing stockholders.
At a 2025 special meeting, holders of approximately 60.17% of the voting stock were present, and a majority approved several key proposals. Stockholders approved a Subscription Agreement covering the private placement of 337,432 common shares and 39,943 shares of Series B Convertible Preferred Stock, the issuance of common shares upon conversion of that preferred stock in excess of a 19.99% share exchange cap, the company’s 2025 Equity Incentive Plan, and the ability to adjourn or postpone the meeting.
Qualigen Therapeutics, Inc. reported a net loss of $2.0 million for the quarter and $6.4 million for the nine months ended September 30, 2025, modestly higher than the prior year. The company’s balance sheet changed significantly after equity financings, with cash and cash equivalents rising to $38.8 million and total assets to $43.5 million, compared with $4.7 million of assets at year-end 2024.
In September 2025, Qualigen closed a $41.0 million Subscription Agreement led by Faraday Future, issuing common stock and new Series B convertible preferred stock. Up to $6.8 million of net proceeds are designated for existing debt repayment and current operations, while the remaining cash and contributed currency are reserved for establishing cryptocurrency treasury operations. Despite the capital raise, recurring losses, limited operating cash, and the early-stage nature of the new crypto strategy led management to conclude there is substantial doubt about the company’s ability to continue as a going concern over the next year.
Qualigen Therapeutics called a special stockholder meeting to seek approval for a recently closed private placement and related share issuances, conversion terms, and a new equity plan. Stockholders are asked to approve the Subscription Agreement and related transactions, including the prior sale of 337,432 shares of common stock and 39,943 shares of Series B Convertible Preferred Stock, and to allow conversion-related issuances above the Nasdaq 19.99% cap.
The Offering totaled $41,000,000 in cash. Series B Preferred carries a $1,000 stated value and is convertible at $2.246 per share after stockholder approval, subject to beneficial ownership limits. The company plans to use up to $6,800,000 of net cash proceeds to pay existing debt and fund operations, with the remainder and contributed currency for establishing cryptocurrency treasury operations.
Stockholders will also vote on a 2025 Equity Incentive Plan equal to 20% of common stock outstanding after the Offering, with a 10% annual evergreen increase through 2046, and on the ability to adjourn the meeting to solicit additional proxies if needed.
Qualigen Therapeutics is asking stockholders to approve the private Offering of $41,000,000 in equity that included 337,432 shares of Common Stock and 39,943 shares of newly created Series B Convertible Preferred Stock.
The Offering closed on September 29, 2025; Common Stock was priced at $2.246 per share and each share of Series B Stock has a $1,000 stated value and converts into Common Stock at a conversion price of $2.246 subject to shareholder approval to permit conversions above a 19.99% exchange cap. The Company plans to use up to $6,800,000 of net proceeds to repay debt and fund operations, with the remainder allocated to establish cryptocurrency treasury operations. Stockholder approval is also requested for a 2025 Equity Incentive Plan with a share reserve equal to 20% of Common Stock outstanding after the Offering and an evergreen 10% annual increase through 2036.
Qualigen Therapeutics reports several governance and audit changes. Its prior auditor, WithumSmith+Brown, resigned effective October 1, 2025, ending engagements for the September 30, 2025 quarterly review and the December 31, 2025 year-end audit. Withum’s report on the year ended December 31, 2024 included an explanatory paragraph about substantial doubt regarding the company’s ability to continue as a going concern, but otherwise was not adverse or qualified, and the company states there were no disagreements or other reportable events beyond previously disclosed material weaknesses in internal control over financial reporting.
The Audit Committee approved Macias Gini & O’Connell LLP as new independent auditor for the 2025 year-end audit and specified interim reviews through September 30, 2026, subject to client acceptance procedures. Effective October 2, 2025, the company appointed Jiawei Wang as Co‑Chief Executive Officer and Koti Meka as Chief Financial Officer, and added three new directors, who also joined key board committees. Three existing directors resigned in connection with a recent private placement, with the company stating these departures were not due to disagreements.
Qualigen Therapeutics (QLGN) closed a $41,000,000 private placement on September 29, 2025, selling 337,432 shares of common stock at $2.246 and 17,783 shares of Series B Convertible Preferred Stock at a $1,000 stated value. The Series B converts into common at a $2.246 conversion price after Stockholder Approval under Nasdaq Rule 5635, with allocations capped at 19.99% ownership per investor at closing.
The company plans to use up to $6,800,000 of net cash proceeds to pay existing debt and fund current operations, with the balance of cash proceeds and contributed currency for establishing cryptocurrency treasury operations. Qualigen agreed to file a resale registration within 45 days of closing and target effectiveness 45 days thereafter (or 60 days if fully reviewed). Univest Securities will receive a 5.5% cash fee, warrants equal to 6% of securities sold at a $2.47 exercise price, and up to $150,000 in expenses. The Lead Investor, Faraday Future Intelligent Electric Inc., secured board designation rights; board changes include appointing Jiawei Wang as Co‑CEO and Koti Meka as CFO, alongside three director resignations.
Qualigen Therapeutics, Inc. reported that its Board of Directors appointed Kevin Chen as an independent director, effective September 26, 2025. As of this appointment, he has not yet been assigned to any Board committees. Chen is currently Chief Economist and CIO of Horizon Financial and serves on several public company boards, including CurrenC Group, Australian Oilseeds Investments, Scage Future and Capitan Investment Ltd. His background includes senior investment roles at Credit Agricole/Amundi Asset Management and Morgan Stanley, as well as academic positions at New York University and other institutions.